Methods of administering anti-ox40 antibodies

Abstract

The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

1 - 130 . (canceled) 
     
     
         131 . A method of enhancing OX40 signaling in a subject, the method comprising administering to the subject an effective amount of an antibody that specifically binds to human OX40, wherein the antibody comprises a VH comprising the amino acid sequence set forth in SEQ ID NO: 16, and a VL comprising the amino acid sequence set forth in SEQ ID NO: 15. 
     
     
         132 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 21, and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         133 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 60, and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         134 . The method of  claim 131 , wherein the subject has cancer. 
     
     
         135 . The method of  claim 134 , wherein the cancer is selected from the group consisting of melanoma, renal cancer, prostate cancer, colon cancer, and lung cancer. 
     
     
         136 . The method of  claim 134 , further comprising administering to the subject one or more selected from the group consisting of: an inhibitor of indoleamine-2,3-dioxygenase (IDO), a vaccine, and a checkpoint targeting agent. 
     
     
         137 . The method of  claim 136 , wherein the inhibitor of IDO is selected from the group consisting of epacadostat, F001287, indoximod, and NLG919. 
     
     
         138 . The method of  claim 136 , wherein the vaccine comprises a heat shock protein peptide complex (HSPPC) comprising a heat shock protein complexed with an antigenic peptide. 
     
     
         139 . The method of  claim 136 , wherein the checkpoint targeting agent is selected from the group consisting of an antagonist anti-PD-1 antibody, an antagonist anti-PD-L1 antibody, an antagonist anti-PD-L2 antibody, an antagonist anti-CTLA-4 antibody, an antagonist anti-TIM-3 antibody, an antagonist anti-LAG-3 antibody, an antagonist anti-CEACAM1 antibody, an agonist anti-GITR antibody, an agonist anti-CD137 antibody, and an agonist anti-OX40 antibody. 
     
     
         140 . A method for enhancing the expansion of T cells and T cell effector function in a subject, the method comprising administering to the subject an effective amount of an antibody that specifically binds to human OX40, wherein the antibody comprises a VH comprising the amino acid sequence set forth in SEQ ID NO: 16, and a VL comprising the amino acid sequence set forth in SEQ ID NO: 15. 
     
     
         141 . The method of  claim 140 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 21, and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         142 . The method of  claim 140 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 60, and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         143 . A method of reducing OX40 signaling in a subject, the method comprising administering to the subject an effective amount of an antibody that specifically binds to human OX40, wherein the antibody comprises a VH comprising the amino acid sequence set forth in SEQ ID NO: 16, and a VL comprising the amino acid sequence set forth in SEQ ID NO: 15. 
     
     
         144 . The method of  claim 143 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 21, and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         145 . The method of  claim 143 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 60, and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         146 . The method of  claim 143 , wherein the subject has an autoimmune or inflammatory disease or disorder. 
     
     
         147 . The method of  claim 146 , wherein the disease or disorder is selected from the group consisting of: transplant rejection, vasculitis, asthma, rheumatoid arthritis, dermatitis, inflammatory bowel disease, uveitis, and lupus. 
     
     
         148 . The method of  claim 143 , wherein the subject has an infectious disease.